Uncategorized
Quarterly net income increases for Regeneron
Regeneron Pharmaceuticals reported first-quarter net income of $98.9 million, up from $11.7 million in the same quarter of the previous year, according to a company news release.Total revenues for the quarter were $440 million, compared with $232 million a year ago. Net product sales were $319 million, compared with $128 million the previous year. Net product sales of Eylea (aflibercept) were $314 million, compared with $124 million in 2012.